Fludrocortisone for POTS: How It Expands Blood Volume and What to Watch For

Fludrocortisone (brand name Florinef) is a synthetic mineralocorticoid — a hormone that acts like aldosterone, the body's natural sodium-retaining hormone — and is one of the most commonly prescribed medications for POTS. Unlike beta-blockers and ivabradine, which address the heart rate component of POTS, fludrocortisone targets the underlying blood volume deficit that drives the condition in many patients.

Mechanism: Expanding Blood Volume

The mineralocorticoid system regulates sodium and fluid balance in the body. Aldosterone, produced by the adrenal glands, acts on the kidneys to increase sodium reabsorption — pulling sodium (and water) back into the bloodstream rather than excreting it in urine. This expands blood volume and raises blood pressure.

Fludrocortisone is a potent synthetic mineralocorticoid with approximately 125 times the mineralocorticoid activity of cortisol. By mimicking aldosterone's action on the kidneys, fludrocortisone causes the kidneys to retain more sodium and water, expanding plasma volume. For POTS patients with hypovolemia (reduced blood volume), this directly addresses one of the primary physiological deficits driving their symptoms.

Fludrocortisone also has some glucocorticoid activity (approximately 10 times that of cortisol), though at the doses used for POTS, this effect is generally clinically insignificant.

Dosing

Fludrocortisone dosing for POTS is considerably lower than doses used for adrenal insufficiency:

Most POTS specialists start at 0.05–0.1 mg once daily (taken in the morning to minimize nocturnal fluid retention and nocturia) and increase gradually based on response. The full effect of fludrocortisone on blood volume takes 1–2 weeks to develop, so assessment of efficacy should not be made too quickly.

What to Expect

The primary expected benefit is a gradual reduction in orthostatic symptoms — less dizziness, reduced heart rate increase upon standing, improved energy — as blood volume expands over 1–2 weeks. Many patients also notice reduced thirst and less frequent urination as the kidneys retain more fluid.

For fludrocortisone to work effectively, adequate sodium and fluid intake is essential. The medication increases the kidneys' capacity to retain sodium, but if dietary sodium intake is low, there is little sodium to retain. Most POTS specialists recommend maintaining a high-sodium diet (3,000–10,000 mg per day) and adequate fluid intake (2–3 liters per day) alongside fludrocortisone.

Side Effects and Monitoring

Fludrocortisone's side effects are primarily related to its mineralocorticoid effects — too much sodium and fluid retention:

Hypokalemia (low potassium). This is the most important side effect to monitor. Fludrocortisone causes the kidneys to excrete potassium in exchange for retaining sodium. Low potassium can cause muscle weakness, cramps, fatigue, palpitations, and in severe cases, cardiac arrhythmias. Potassium levels should be checked within 1–2 weeks of starting fludrocortisone and periodically thereafter. Many patients require potassium supplementation (potassium chloride tablets or potassium-rich foods) to maintain normal levels.

Supine hypertension. Expanding blood volume raises blood pressure. For POTS patients with already-low blood pressure, this is often beneficial. However, some patients — particularly those with hyperadrenergic POTS — develop elevated blood pressure when lying down. Monitoring blood pressure both lying and standing is important.

Edema. Fluid retention can cause ankle swelling and, in some patients, more generalized edema. Elevating the legs and wearing compression garments can help. If edema is significant, the dose may need to be reduced.

Headache. Some patients experience headaches, possibly related to increased intracranial pressure from fluid retention. This is more common at higher doses.

Acne and other glucocorticoid effects. At the doses used for POTS, glucocorticoid side effects (weight gain, mood changes, immunosuppression) are generally not significant, but can occur in sensitive individuals.

Monitoring Schedule

Patients on fludrocortisone should have the following monitored:

• Serum potassium: At baseline, 1–2 weeks after starting, and every 3–6 months thereafter
• Blood pressure (lying and standing): At each clinic visit
• Weight: Regular monitoring for excessive fluid retention
• Symptoms of hypokalemia: Muscle cramps, weakness, palpitations

Who Benefits Most from Fludrocortisone

Fludrocortisone is most effective for POTS patients with:

• Documented hypovolemia (low blood volume on nuclear medicine blood volume study)
• Low or normal blood pressure
• Symptoms that worsen with dehydration or heat
• Inadequate response to non-pharmacological measures alone

Fludrocortisone is less suitable for patients with:

• Supine hypertension
• Significant edema
• Kidney disease
• Heart failure
• Known hypokalemia that is difficult to correct

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.